Renal Cell Carcinoma
631
91
156
250
Key Insights
Highlights
Success Rate
72% trial completion
Published Results
123 trials with published results (19%)
Research Maturity
250 completed trials (40% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
15.2%
96 terminated out of 631 trials
72.3%
-14.3% vs benchmark
6%
36 trials in Phase 3/4
49%
123 of 250 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 250 completed trials
Clinical Trials (631)
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
DESTINY-PANTUMOUR04
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
Use of Tracking Devices to Locate Abnormalities During Invasive Procedures
89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
Assessment of Quality of Life and Outcomes in Patients With Primary Renal Cell Carcinoma Treated With SBRT
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
ITIL-306 in Advanced Solid Tumors
Follow-up After Metastasectomy in Patients With Kidney Cancer
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours